KM12Homo sapiens (Human)Cancer cell line
Also known as: KM-12, KM.12, KIM12
Quick Overview
Human colon cancer cell line with known mutations and drug sensitivity profiles.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1331 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Colon[UBERON:UBERON_0001155] |
Donor Information
| Age Category | Unknown |
|---|---|
| Sex | Unknown |
| Subtype Features | MSI |
Disease Information
| Disease | Colon carcinoma |
|---|---|
| Lineage | Bowel |
| Subtype | Colon Adenocarcinoma |
| OncoTree Code | COAD |
DepMap Information
| Source Type | JCRB |
|---|---|
| Source ID | ACH-000969_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| Gene fusion | NTRK1 | TPM3-NTRK1 | - | - | from parent cell line KM12 |
| MutationSimple | ACVR2A | p.Lys437Argfs*5 (c.1310delA) | Homozygous | - | PubMed=12615714 |
| MutationSimple | APC | p.Asn1819fs*7 (c.5454_5455insA) | Heterozygous | - | from parent cell line KM12 |
| MutationSimple | BRAF | p.Ala404Cysfs*9 (c.1208dupC) (p.Pro403fs) | Heterozygous | - | Unknown, PubMed=28683746 |
| MutationSimple | BRCA2 | p.Asn1784Hisfs*7 (c.5350_5351delAA) | Heterozygous | - | from parent cell line KM12 |
| MutationSimple | PTEN | p.Gly129Ter (c.385G>T) | Heterozygous | - | from parent cell line KM12 |
| MutationSimple | PTEN | p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA) | Heterozygous | - | Unknown, Unknown, PubMed=25230021 |
| MutationSimple | TGFBR2 | p.Lys128Serfs*35 (c.383delA) | Homozygous | - | PubMed=12615714 |
| MutationSimple | TP53 | p.Val73Trpfs*50 (c.216delC) (p.P72fs) | Heterozygous | - | Unknown, Unknown, PubMed=9887230 |
| MutationSimple | TP53 | p.His179Arg (c.536A>G) | Unspecified | - | PubMed=35297208 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Differential effector engagement by oncogenic KRAS.";
McCormick F.
Cell Rep. 22:1889-1902(2018).
Genomic determinants of protein abundance variation in colorectal cancer cells.
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.
Cell Rep. 20:2201-2214(2017).
Multi-omics of 34 colorectal cancer cell lines -- a resource for biomedical studies.
Myklebost O., Skotheim R.I., Sveen A., Lothe R.A.
Mol. Cancer 16:116.1-116.16(2017).
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.
J. Natl. Cancer Inst. 83:757-766(1991).
Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.
Sparks A.B., Morin P.J., Vogelstein B., Kinzler K.W.
Cancer Res. 58:1130-1134(1998).
Systematic variation in gene expression patterns in human cancer cell lines.
Botstein D., Brown P.O.
Nat. Genet. 24:227-235(2000).
Short tandem repeat profiling provides an international reference standard for human cell lines.
Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.
Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers.
Willson J.K.V., Yeo C.J., Hruban R.H., Kern S.E.
Cancer Res. 63:994-999(2003).
HLA class I and II genotype of the NCI-60 cell lines.";
Morse H.C. 3rd, Stroncek D., Marincola F.M.
J. Transl. Med. 3:11.1-11.8(2005).
p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.
Tomoda H., Yamori T., Tsuruo T.
J. Natl. Cancer Inst. 97:765-777(2005).
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mol. Cancer Ther. 5:2606-2612(2006).
DNA fingerprinting of the NCI-60 cell line panel.";
Chanock S.J., Weinstein J.N.
Mol. Cancer Ther. 8:713-724(2009).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
Genomic and biological characterization of exon 4 KRAS mutations in human cancer.
Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.
Cancer Res. 70:5901-5911(2010).
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Ambudkar S.V., Gottesman M.M.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
Kong D.-X., Yamori T.
Bioorg. Med. Chem. 20:1947-1951(2012).
Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.
Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.
PLoS ONE 7:E31628-E31628(2012).
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
Yoon C.N., Chang Y.-T.
PLoS ONE 7:E32096-E32096(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Science 336:1040-1044(2012).
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
Cancer Res. 73:4372-4382(2013).
Global proteome analysis of the NCI-60 cell line panel.";
Wilhelm M., Kuster B.
Cell Rep. 4:609-620(2013).
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Hirshfield K.M., Oltvai Z.N., Vazquez A.
Cancer Metab. 1:20.1-20.13(2013).
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
PLoS ONE 9:E92047-E92047(2014).
The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.
Siena S., Veronese S., Galvani A., Isacchi A.
Mol. Oncol. 8:1495-1507(2014).
Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.
Mariadason J.M., Sieber O.M.
Cancer Res. 74:3238-3247(2014).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.
Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.
Nat. Commun. 6:7002.1-7002.10(2015).
Highly expressed genes in rapidly proliferating tumor cells as new targets for colorectal cancer treatment.
Sanchez A., Schwartz S. Jr., Bilic J., Mariadason J.M., Arango D.
Clin. Cancer Res. 21:3695-3704(2015).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
N-glycosylation profiling of colorectal cancer cell lines reveals association of fucosylation with differentiation and caudal type homebox 1 (CDX1)/villin mRNA expression.
Tollenaar R.A.E.M., Rombouts Y., Wuhrer M.
Mol. Cell. Proteomics 15:124-140(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Vandesompele J.
Sci. Data 3:160052-160052(2016).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
Mob. DNA 7:20.1-20.11(2016).